Transduction of the central nervous system after intracerebroventricular injection of adeno-associated viral vectors in neonatal and juvenile mice
Open accessAbstract
Several neurodevelopmental and neurodegenerative disorders affecting the central nervous system are potentially treatable via viral vector-mediated gene transfer. Adeno-associated viral (AAV) vectors have been used in clinical trials because of their desirable properties including a high degree of safety, efficacy, and stability. Major factors affecting tropism, expression level, and cell type specificity of AAV-mediated transgenes include encapsidation of different AAV serotypes, promoter selection, and the timing of vector administration. In this study, we evaluated the ability of single-stranded AAV2 vectors pseudotyped with viral capsids from serotype 9 (AAV2/9) to transduce the brain and target gene expression to specific cell types after intracerebroventricular injection into mice. Titer-matched AAV2/9 vectors encoding the enhanced green fluorescent protein (eGFP) reporter, driven by the cytomegalovirus (CMV) promoter, or the neuron-specific synapsin-1 promoter, were injected bilaterally into the lateral ventricles of C57/BL6 mice on postnatal day 5 (neonatal) or 21 (juvenile). Brain sections were analyzed 25 days after injection, using immunocytochemistry and confocal microscopy. eGFP immunohistochemistry after neonatal and juvenile administration of viral vectors revealed transduction throughout the brain including the striatum, hippocampus, cerebral cortex, and cerebellum, but with different patterns of cell-specific gene expression. eGFP expression was seen in astrocytes after treatment on postnatal day 5 with vectors carrying the CMV promoter, expanding the usefulness of AAVs for modeling and treating diseases involving glial cell pathology. In contrast, injection of AAV2/9-CMV-eGFP on postnatal day 21 resulted in preferential transduction of neurons. Administration of AAV2/9-eGFP with the synapsin-1 promoter on either postnatal day 5 or 21 resulted in widespread neuronal transduction. These results outline efficient methods and tools for gene delivery to the nervous system by direct, early postnatal administration of AAV vectors. Our findings highlight the importance of promoter selection and age of administration on the intensity, distribution, and cell type specificity of AAV transduction in the brain.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Age can have a profound impact on the tropism of individual vector systems.
“age can have a profound impact on the tropism of individual vector systems.”
From Preclinical biodistribution, tropism, and efficacy of oligotropic AAV/Olig001 in a mouse model of congenital white matter disease (2021) · cites this paper as [13]
Cites
The mouse brain in stereotaxic coordinates
Konsman, J. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(03)00088-x · Cited by 16,796 · see citing works
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 12,859 · see citing works
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456 · cited 8× · see citing works
“intravenous injections has been reported in another study using AAV2/9-GFP vectors (Foust et al., 2009).”
InfluentialAdeno-associated Virus Serotypes: Vector Toolkit for Human Gene Therapy
Wu, Z., Asokan, A., & Samulski, R. J. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.009 · Cited by 921 · see citing works
Marks, W. J., Bartus, R. T., Siffert, J. O., Davis, C. S., Lozano, A. M., Boulis, N. M., Vitek, J. L., Stacy, M. A., Turner, D. A., Verhagen, L., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70254-4 · Cited by 685 · see citing works
LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Thomas, K., Sarkar, A., Siddiqui, M. S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70039-4 · Cited by 681 · see citing works
Davidson, B. L., Stein, C. S., Heth, J., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, J., Ghodsi, A., & Chiorini, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050581197 · Cited by 679 · see citing works
Davidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, J., Ghodsi, A., & Chiorini, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3428 · Cited by 531 · see citing works
Duque, S., Joussemet, B., Riviere, C., Marais, T., Dubreil, L., Douar, A.-M., Fyfe, J., Moullier, P., Colle, M.-A., & Barkats, M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.71 · Cited by 511 · see citing works
Gray, S. J., Foti, S. B., Schwartz, J. W., Bachaboina, L., Taylor-Blake, B., Coleman, J., Ehlers, M. D., Zylka, M. J., McCown, T. J., & Samulski, R. J. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.245 · Cited by 420 · see citing works
Cearley, C. N., & Wolfe, J. H. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.015 · Cited by 409 · see citing works
Long-Term Evaluation of a Phase 1 Study of AADC Gene Therapy for Parkinson's Disease
Mittermeyer, G., Christine, C. W., Rosenbluth, K. H., Baker, S. L., Starr, P. A., Larson, P., Kaplan, P. L., Forsayeth, J., Aminoff, M. J., & Bankiewicz, K. S. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.220 · Cited by 297 · see citing works
Zhang, H., Yang, B., Mu, X., Ahmed, S. S., Su, Q., He, R., Wang, H., Mueller, C., Sena-Esteves, M., Brown, R., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.98 · Cited by 291 · see citing works
Loeb, J. E., Cordier, W. S., Harris, M. E., Weitzman, M. D., & Hope, T. J. (1999) · Human Gene Therapy · doi:10.1089/10430349950016942 · Cited by 279 · see citing works
Adeno-associated virus: from defective virus to effective vector
Gonçalves, M. A. F. V. (2005) · Virology Journal · doi:10.1186/1743-422x-2-43 · Cited by 266 · see citing works
Passini, M. A., Watson, D. J., Vite, C. H., Landsburg, D. J., Feigenbaum, A. L., & Wolfe, J. H. N. (2003) · Journal of Virology · doi:10.1128/jvi.77.12.7034-7040.2003 · Cited by 213 · see citing works
Adeno-Associated Virus (AAV) Vectors in the CNS
McCown, T. J. (2005) · Current Gene Therapy · doi:10.2174/1566523054064995 · Cited by 187 · see citing works
Gray, S. J., Blake, B. L., Criswell, H. E., Nicolson, S. C., Samulski, R. J., & McCown, T. J. (2010) · Molecular Therapy · doi:10.1038/mt.2009.292 · Cited by 185 · see citing works
Gadalla, K. K. E., Bailey, M. E. S., SPIKE, R. C., Ross, P. D., Woodard, K., Kalburgi, S. N., Bachaboina, L., Deng, J. V., West, A. E., Samulski, R. J., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.200 · Cited by 157 · see citing works
Adeno-associated virus (AAV) gene therapy for neurological disease
Weinberg, M. S., Samulski, R. J., & McCown, T. J. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.03.004 · Cited by 154 · see citing works
Fu, H., Lu, K., Jennings, J. S., Moy, S. S., Perez, A., DiRosario, J., McCarty, D. M., & Muenzer, J. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302961 · Cited by 100 · see citing works
Rahim, A. A., Wong, A. M. S., Hoefer, K., Buckley, S. M. K., Mattar, C. N. Z., Cheng, S. H., Chan, J. K. Y., Cooper, J. D., & Waddington, S. N. (2011) · The FASEB Journal · doi:10.1096/fj.11-182311 · Cited by 95 · see citing works
Adeno-Associated Virus (AAV) Vectors in the CNS
McCown, T. J. (2011) · Current Gene Therapy · doi:10.2174/156652311795684759 · Cited by 85 · see citing works
Zuleta, A., Vidal, R. L., Armentano, D., Parsons, G., & Hetz, C. A. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.03.033 · Cited by 84 · see citing works
Ghodsi, A., Stein, C. S., Derksen, T. A., Martins, I., Anderson, R. D., & Davidson, B. L. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7205 · Cited by 77 · see citing works
Mattar, C. N. Z., Waddington, S. N., Biswas, A., Johana, N. B., Ng, X., Fisk, A. S., Fisk, N. M., Tan, L. G., Rahim, A. A., Buckley, S. M. K., et al. (2012) · Gene Therapy · doi:10.1038/gt.2011.216 · Cited by 73 · see citing works
Zeier, Z. R., Kumar, A., Bodhinathan, K., Feller, J. A., Foster, T. C., & Bloom, D. C. (2009) · Gene Therapy · doi:10.1038/gt.2009.83 · Cited by 68 · see citing works
Gene therapy for Huntington's disease
Ramaswamy, S., & Kordower, J. H. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.030 · Cited by 57 · see citing works
Pathways to Drug Development for Autism Spectrum Disorders
Hampson, D. R., Gholizadeh, S., & Pacey, L. K. K. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.245 · Cited by 55 · see citing works
Cederfjäll, E. A., Şahin, G., Kirik, D., & Björklund, T. (2012) · Molecular Therapy · doi:10.1038/mt.2012.1 · Cited by 37 · see citing works
Recombinant AAV Delivery to the Central Nervous System
Bockstael, O., Foust, K. D., Kaspar, B. K., & Tenenbaum, L. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-370-7_7 · Cited by 10 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Meyer, K., Ferraiuolo, L., Schmelzer, L., Braun, L., McGovern, V., Likhite, S., Michels, O., Govoni, A., Fitzgerald, J., Morales, P., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.210 · Cited by 286 · see citing works
Gholizadeh, S., Arsenault, J., Xuan, I., Pacey, L. K., & Hampson, D. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.167 · Cited by 83 · see citing works
Jackson, K. L., Dayton, R. D., Deverman, B. E., & Klein, R. L. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00116 · Cited by 77 · see citing works
Current and potential new treatment strategies for creatine deficiency syndromes
Fernandes‐Pires, G., & Braissant, O. (2021) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2021.12.005 · Cited by 75 · see citing works
Prospects for mTOR-mediated functional repair after central nervous system trauma
Berry, M., Ahmed, Z., Morgan-Warren, P. J., Fulton, D. J., & Logan, A. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.10.002 · Cited by 69 · see citing works
Jackson, K. L., Dayton, R. D., Deverman, B. E., & Klein, R. L. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00154 · Cited by 69 · see citing works
FMRP Expression Levels in Mouse Central Nervous System Neurons Determine Behavioral Phenotype
Arsenault, J., Gholizadeh, S., Niibori, Y., Pacey, L. K. K., Halder, S. K., Koxhioni, E., Konno, A., Hirai, H., & Hampson, D. R. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.090 · Cited by 66 · see citing works
Woodworth, H. L., Perez‐Bonilla, P., Beekly, B. G., Lewis, T. J., & Leinninger, G. M. (2018) · eNeuro · doi:10.1523/eneuro.0191-17.2018 · Cited by 64 · see citing works
AAV9-mediated central nervous system–targeted gene delivery via cisterna magna route in mice
Lukashchuk, V., Lewis, K. E. A., Coldicott, I., Grierson, A. J., & Azzouz, M. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.55 · Cited by 58 · see citing works
Ye, D., Chukwu, C., Yang, Y., Hu, Z., & Chen, H. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115363 · Cited by 58 · see citing works
Destination Brain: the Past, Present, and Future of Therapeutic Gene Delivery
Joshi, C. R., Labhasetwar, V., & Ghorpade, A. (2017) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-016-9724-3 · Cited by 55 · see citing works
Molecular approaches for manipulating astrocytic signaling in vivo
Xie, A. X., Petravicz, J., & McCarthy, K. D. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00144 · Cited by 55 · see citing works
Sohn, J., Takahashi, M., Okamoto, S., Ishida, Y., Furuta, T., & Hioki, H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169611 · Cited by 55 · see citing works
Fee, C., Prévot, T. D., Misquitta, K. A., Knutson, D. E., Li, G., Mondal, P., Cook, J. M., Banasr, M., & Sibille, E. L. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab002 · Cited by 45 · see citing works
Gerits, A., Vancraeyenest, P., Vreysen, S., Laramée, M., Michiels, A., Gijsbers, R., den Haute, C. V., Moons, L., Debyser, Z., Baekelandt, V., et al. (2015) · Neurophotonics · doi:10.1117/1.nph.2.3.031209 · Cited by 44 · see citing works
Francis, J. S., Markov, V., Wojtas, I. D., Gray, S., McCown, T., Samulski, R. J., Figueroa, M., & Leone, P. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.01.009 · Cited by 41 · see citing works
“Although we have generated preliminary data supporting this in neonatal animals,(4) age can have a profound impact on the tropism of individual vector systems.(13) The current study was undertaken to assess the ability of AAV/ Olig001 to target oligodendrocytes in symptomatic animals that model Canavan disease at a st…”
ResultReversibility of motor dysfunction in the rat model of NGLY1 deficiency
Asahina, M., Fujinawa, R., Hirayama, H., Tozawa, R., Kajii, Y., & Suzuki, T. (2021) · Molecular Brain · doi:10.1186/s13041-021-00806-6 · Cited by 32 · see citing works
Hooper, A. W. M., Wong, H., Niibori, Y., Abdoli, R., Karumuthil‐Melethil, S., Qiao, C., Danos, O., Bruder, J. T., & Hampson, D. R. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.06.013 · Cited by 31 · see citing works
Shumar, S. A., Fagone, P., Alfonso-Pecchio, A. R., Gray, J. T., Rehg, J. E., Jackowski, S., & Leonardi, R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130013 · Cited by 29 · see citing works
Benefits of Neuronal Preferential Systemic Gene Therapy for Neurotransmitter Deficiency
Lee, N., Muramatsu, S., Chien, Y., Liu, W.-S., Wang, W., Cheng, C.-H., Hu, M.-K., Chen, P.-W., Tzen, K., Byrne, B. J., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.122 · Cited by 26 · see citing works
Matsuzaki, Y., Konno, A., Mukai, R., Honda, F., Hirato, M., Yoshimoto, Y., & Hirai, H. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9777-6 · Cited by 24 · see citing works
Neonatal neuronal WWOX gene therapy rescues Wwox null phenotypes
Repudi, S., Kustanovich, I. M., Abu‐Swai, S., Stern, S., & Aqeilan, R. I. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114599 · Cited by 23 · see citing works
Yang, C., Tian, Y., Su, F., Wang, Y., Liu, M., Wang, H., Cui, Y., Yuan, P., Li, X., Li, A., et al. (2021) · Protein & Cell · doi:10.1007/s13238-021-00878-z · Cited by 23 · see citing works
Parker, E. M., Kindja, N. L., Cheetham, C. E. J., & Sweet, R. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-65942-w · Cited by 20 · see citing works
Torregrosa, T., Lehman, S., Hana, S., Marsh, G., Xu, S., Koszka, K., Mastrangelo, N., McCampbell, A., Henderson, C. E., & Lo, S. (2021) · Gene Therapy · doi:10.1038/s41434-021-00223-3 · Cited by 21 · see citing works
Tharmalingam, S., Wu, C., & Hampson, D. R. (2015) · Developmental Neurobiology · doi:10.1002/dneu.22321 · Cited by 19 · see citing works
Prabhakar, S., Zhang, X., Goto, J., Han, S., Lai, C. P., Bronson, R. T., Sena‐Esteves, M., Ramesh, V., Stemmer-Rachamimov, A. O., Kwiatkowski, D. J., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.04.018 · Cited by 19 · see citing works
Wang, W.-Z., Li, M., Chen, Y., Liu, L., Xu, Y., Xia, Z.-H., Yu, Y., Wang, X., Chen, W., Zhang, F., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210463 · Cited by 18 · see citing works
Donsante, A., McEachin, Z. T., Riley, J. S., Leung, C. H., Kanz, L., O’Connor, D. M. A., & Boulis, N. M. (2016) · Gene Therapy · doi:10.1038/gt.2016.6 · Cited by 18 · see citing works
Paradoxical role of PKA inhibitor on amyloidβ-induced memory deficit
Amini, E., Nassireslami, E., Payandemehr, B., Khodagholi, F., Foolad, F., Khalaj, S., Hamedani, M. P., Azimi, L., & Sharifzadeh, M. S. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.05.029 · Cited by 15 · see citing works
Reaching for the Stars in the Brain: Polymer-Mediated Gene Delivery to Human Astrocytes
Joshi, C., Raghavan, V., Vijayaraghavalu, S., Gao, Y., Saraswathy, M., Labhasetwar, V. D., & Ghorpade, A. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.06.009 · Cited by 14 · see citing works
A Molecular Reporter for Monitoring Autophagic Flux in Nervous System In Vivo
Castillo, K., Valenzuela, V., Oñate, M., & Hetz, C. A. (2016) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2016.09.077 · Cited by 14 · see citing works
Liu, R., Wang, H., Wang, H., Sun, Y., Su, Y., Wang, X., Li, J., & Si, T. (2019) · Hippocampus · doi:10.1002/hipo.23098 · Cited by 13 · see citing works
Gilkes, J. A., Judkins, B. L., Herrera, B. N., Mandel, R. J., Boye, S. L., Boye, S. L., Srivastava, A., & Heldermon, C. D. (2020) · Gene Therapy · doi:10.1038/s41434-020-00206-w · Cited by 13 · see citing works
Arsenault, J., Hooper, A. W. M., Gholizadeh, S., Kong, T., Pacey, L. K. K., Koxhioni, E., Niibori, Y., Eubanks, J. H., Wang, L., & Hampson, D. R. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa226 · Cited by 12 · see citing works
CNS-dominant human FMRP isoform rescues seizures, fear, and sleep abnormalities in Fmr1-KO mice
Wong, H., Hooper, A. W. M., Kang, H. R., Lee, S. J., Zhao, J., Sadhu, C., Rawat, S. S., Gray, S. J., & Hampson, D. R. (2023) · JCI Insight · doi:10.1172/jci.insight.169650 · Cited by 11 · see citing works
Kakava-Georgiadou, N., Zwartkruis, M. M., Bullich‐Vilarrubias, C., Luijendijk, M. C. M., Garner, K. M., van der Plasse, G., & Adan, R. A. H. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00049 · Cited by 10 · see citing works
Hashimoto, H., Mizushima, T., Ogura, T., Kagawa, T., Tomiyama, K., Takahashi, R., Yagoto, M., Kawai, K., Chijiwa, T., Nakamura, M., et al. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.08.104 · Cited by 9 · see citing works
Parker, E. M., Kindja, N. L., DeGiosio, R. A., Salisbury, R. B., Krivinko, J. M., Cheetham, C. E. J., MacDonald, M. L., Fan, W., Cheng, B., & Sweet, R. A. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03181-7 · Cited by 8 · see citing works
Xu, Y., He, F., Qi, F., Yang, G., Zheng, F., Yang, J., Wang, X., Liu, J., & Zou, J. (2017) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2017.03.002 · Cited by 8 · see citing works
Regioselective Biolistic Targeting in Organotypic Brain Slices Using a Modified Gene Gun
Arsenault, J., Nagy, A., Henderson, J. T., & O’Brien, J. (2014) · Journal of Visualized Experiments · doi:10.3791/52148 · Cited by 7 · see citing works
Yu, J.-H., Nam, B.-G., Kim, M., Pyo, S., Seo, J. H., & Cho, S. (2021) · Genes · doi:10.3390/genes12050712 · Cited by 7 · see citing works
Peelaerts, W., Brito, F., den Haute, C. V., Janer, A. B., Steiner, J. A., Brundin, P., & Baekelandt, V. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.012 · Cited by 7 · see citing works
Castillo, X., Ortiz, G., Arnold, E., Wu, Z., Tovar‐y‐Romo, L. B., Clapp, C., & de la Escalera, G. M. (2024) · Journal of Neuroendocrinology · doi:10.1111/jne.13415 · Cited by 4 · see citing works
Polyserine peptides are toxic and exacerbate tau pathology in micePreprint
Alstyne, M. V., Nguyen, V. L., Hoeffer, C. A., & Parker, R. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.10.616100 · Cited by 4 · see citing works
Xu, Y., Wu, T., Lo, L. T., Ko, C., Wang, X., & Ma, C. H. E. (2025) · Advanced Science · doi:10.1002/advs.202505421 · Cited by 2 · see citing works
AAV9-mediated NGLY1 gene replacement suppresses non-epileptic convulsions in Ngly1 rats
Asahina, M., Fujinawa, R., Hirayama, H., Yukitake, H., & Suzuki, T. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152823 · Cited by 2 · see citing works
Regioselective Biolistic Targeting in Organotypic Brain Slices Using a Modified Gene Gun
Arsenault, J., Nagy, A., Henderson, J. T., & O’Brien, J. (2014) · Journal of Visualized Experiments · doi:10.3791/52148-v · Cited by 2 · see citing works
Polyserine domains are toxic and exacerbate tau pathology in mice
Alstyne, M. V., Nguyen, V. L., Hoeffer, C. A., & Parker, R. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2527425122 · Cited by 1 · see citing works
Quantifying Dendritic Arbors In Vitro and In Vivo in Rodent Models
Wilson, R. J., Badley, J. R., & Lein, P. J. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3969-6_4 · Cited by 1 · see citing works
Keegan, A., Çetin, Ö., Chilcott, E. M., Diaz, J. F. A., Eaton, S. D., Waddington, S. N., Counsell, J. R., Rahman, S., & Karda, R. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201781 · Cited by 1 · see citing works
Viral Vectors for Studying Drug-Seeking Behavior
Martínez-Rivera, A., Burgdorf, C. E., & Rajadhyaksha, A. M. (2020) · Neuromethods · doi:10.1007/978-1-0716-1146-3_12 · Cited by 1 · see citing works
Tharmalingam, S. (2014) · TSpace (University of Toronto)
The role of basal ganglia circuitry in motivation
Poyraz, F. C. (2016) · doi:10.7916/d89z94qz
Chen, D., & Lee, S. (2021) · Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · doi:10.26685/urncst.211
Gunabalasingam, J., & Aggarwal, K. (2021) · Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · doi:10.26685/urncst.224
김민지 (2018) · YUHSpace (Yonsei University Medical Library)
CACNB4 overexpression decreases dendritic spine density in sex-specific mannerPreprint
Parker, E. M., Kindja, N. L., DeGiosio, R. A., Salisbury, R. B., Krivinko, J. M., Cheetham, C. E. J., MacDonald, M. L., & Sweet, R. A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.02.478824
Huang, Y., Xie, Y., Liu, L., Fan, D., Le, W., Zhang, X., Peng, T., Li, W., Lin, H., He, L., et al. (2025) · Neuroscience Letters · doi:10.1016/j.neulet.2025.138447
- Authors
- Gholizadeh, S., Tharmalingam, S., MacAldaz, M. E., & Hampson, D. R.
- Affiliations
- University of Toronto (CA)
- Corresponding author
- Hampson, David R.
- Venue
- Human Gene Therapy Methods
- Publisher
- SAGE Publications
- Published
- 2013-08
- Volume
- 24
- Issue
- 4
- Pages
- 205-213
- ISSN
- 1946-6536 (ISSN-L)
- 1946-6544
- PMC
- PMC3753728
- OpenAlex
- W2092875929
- Cited by
- 61
- References
- 31
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 5 · 2023: 1 · 2022: 1 · 2021: 13 · 2020: 4 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 9 · 2015: 8 · 2014: 5
- FWCI
- 4.85
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Human Gene Therapy Methods (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- adeno-associated virus vectors, AAV2/9, intracerebroventricular administration, cytomegalovirus promoter, cell type-specific gene expression, neuronal transduction
- MeSH terms
- Dependovirus, Animals, Brain, Genetic Vectors, Injections, Intraventricular, Mice, Inbred C57BL, Organ Specificity, Transduction, Genetic, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
